TPST
Tempest Therapeutics, Inc. Common StockstockNASDAQ
tempest therapeutics is a development-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways. tempest has a balanced and deep pipeline consisting of first-in-class and best-in-class small molecule therapeutics, which modulate distinct immune response pathways relevant to mounting an effective anti-tumor response. the molecules were developed by inception sciences, a versant ventures affiliated drug discovery engine. tempest has assembled a highly experienced team of small molecule and immuno-oncology drug developers to advance these programs to the clinic across diverse cancers representing significant unmet medical need. tempest is backed by a syndicate of leading us and china based venture capital firms.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.38 | 2026-11-12 | -19.84% | 4.596 |
| 1M | 0.60 | 2026-10-19 | -48.84% | 2.606 |
| 3M | 1.07 | 2026-08-19 | -71.31% | 0.952 |
| 6M | 1.78 | 2026-05-19 | -82.75% | 0.612 |
| 1Y | 4.75 | 2025-11-19 | -93.54% | 0.987 |
| 2Y | 11.25 | 2024-11-19 | -97.27% | — |
| 5Y | 137.41 | 2021-11-19 | -99.78% | 2.518 |
Tempest Therapeutics, Inc. Common Stock (NASDAQ:TPST) stock price today is $0.31, and today's volume is 196,472. TPST is down 6.202% today. The 30 day average volume is 201,899. TPST market cap is $6.14M with 20.00M shares outstanding.